Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma

NCT02923778 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02923778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02923778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 31, 2019
Completion date
December 29, 2026
Enrollment
40 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

leiomyosarcoma, liposarcoma, sarcoma g2, sarcoma g3, soft tissue sarcoma, soft tissue sarcoma of the trunk and extremities, stage i soft tissue sarcoma ajcc v7, stage ii soft tissue sarcoma ajcc v7, undifferentiated pleomorphic sarcoma